BRPI0911259A2 - composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos - Google Patents
composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostosInfo
- Publication number
- BRPI0911259A2 BRPI0911259A2 BRPI0911259A BRPI0911259A BRPI0911259A2 BR PI0911259 A2 BRPI0911259 A2 BR PI0911259A2 BR PI0911259 A BRPI0911259 A BR PI0911259A BR PI0911259 A BRPI0911259 A BR PI0911259A BR PI0911259 A2 BRPI0911259 A2 BR PI0911259A2
- Authority
- BR
- Brazil
- Prior art keywords
- vitro
- compounds
- compound
- pharmaceutical composition
- polymerase activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 101710112514 Host translation inhibitor 5b Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/30—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4521908P | 2008-04-15 | 2008-04-15 | |
| US4521408P | 2008-04-15 | 2008-04-15 | |
| US10985608P | 2008-10-30 | 2008-10-30 | |
| US11791608P | 2008-11-25 | 2008-11-25 | |
| US14833709P | 2009-01-29 | 2009-01-29 | |
| PCT/US2009/040567 WO2009134616A2 (en) | 2008-04-15 | 2009-04-14 | Novel inhibitors of hepatitis c virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0911259A2 true BRPI0911259A2 (pt) | 2015-10-06 |
Family
ID=41078055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0911259A BRPI0911259A2 (pt) | 2008-04-15 | 2009-04-14 | composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090257979A1 (enExample) |
| EP (1) | EP2283002A2 (enExample) |
| JP (1) | JP2011516610A (enExample) |
| KR (1) | KR20110004439A (enExample) |
| CN (1) | CN102026990A (enExample) |
| AU (1) | AU2009241514A1 (enExample) |
| BR (1) | BRPI0911259A2 (enExample) |
| CA (1) | CA2720846A1 (enExample) |
| MX (1) | MX2010011307A (enExample) |
| WO (1) | WO2009134616A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2056675T3 (pl) | 2006-10-12 | 2019-08-30 | Galera Labs, Llc | Metody leczenia zapalenia błony śluzowej jamy ustnej |
| WO2011049988A2 (en) * | 2009-10-20 | 2011-04-28 | Eiger Biopharmaceuticals, Inc. | Indazoles to treat flaviviridae virus infection |
| TW201121968A (en) * | 2009-11-09 | 2011-07-01 | Intermune Inc | Novel inhibitors of hepatitis C virus replication |
| AU2012316397B2 (en) * | 2011-09-26 | 2016-07-21 | Galera Labs, Llc | Methods for treatment of diseases |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
| CN105991908B (zh) * | 2015-03-16 | 2019-06-07 | 迈科威特株式会社 | 摄像机模块用滤光器转换装置及包含该模块的移动设备 |
| US10597415B2 (en) | 2015-08-11 | 2020-03-24 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2017192740A2 (en) | 2016-05-03 | 2017-11-09 | Galera Labs, Llc | Combination therapy for cancer treatment |
| CA3035766A1 (en) | 2016-09-01 | 2018-03-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
| IL295620B2 (en) | 2017-04-13 | 2024-01-01 | Galera Labs Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6025984A (ja) * | 1983-07-22 | 1985-02-08 | Tokyo Inst Of Technol | ベンゾチアジアジン誘導体の製造方法 |
| JPH0216448A (ja) * | 1988-07-04 | 1990-01-19 | Fuji Photo Film Co Ltd | 化学物質の分配係数の推算処理方法 |
| WO1997026265A1 (en) * | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
| US6156700A (en) * | 1997-09-17 | 2000-12-05 | American Cyanmid Company | 3-(1,2-Benzisothiazol- and isoxazol-5-yl)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3H)-pyrimidinone or thione herbicidal agents |
| US6943159B1 (en) * | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
| US20040162285A1 (en) * | 2002-11-01 | 2004-08-19 | Pratt John K. | Anti-infective agents |
| US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
| US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| US7902203B2 (en) * | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
| DE60335564D1 (de) * | 2002-11-01 | 2011-02-10 | Abbott Lab | Antiinfektiöse mittel |
| KR20050122220A (ko) * | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| US7378414B2 (en) * | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| JP4624419B2 (ja) * | 2004-08-23 | 2011-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性へテロ環化合物 |
| US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| WO2006093801A1 (en) * | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
| AU2006243245A1 (en) * | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2656000C (en) * | 2006-06-22 | 2016-09-06 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
| JP4199273B2 (ja) * | 2006-08-29 | 2008-12-17 | 本田技研工業株式会社 | 車両状態推定装置 |
| CL2007003587A1 (es) * | 2006-12-12 | 2008-07-04 | Anadys Pharmaceuticals Inc | Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c. |
| US20080188466A1 (en) * | 2006-12-21 | 2008-08-07 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| MX2009008099A (es) * | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| US20080227774A1 (en) * | 2007-03-15 | 2008-09-18 | Frank Ruebsam | 5,5-disubstituted-indolizinone compounds |
| US7834009B2 (en) * | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
| CN102316871B (zh) * | 2008-06-10 | 2014-06-04 | 安那迪斯药品股份有限公司 | [1，2，4]噻二嗪1，1-二氧化合物 |
-
2009
- 2009-04-14 AU AU2009241514A patent/AU2009241514A1/en not_active Abandoned
- 2009-04-14 EP EP09739418A patent/EP2283002A2/en not_active Withdrawn
- 2009-04-14 KR KR1020107025281A patent/KR20110004439A/ko not_active Withdrawn
- 2009-04-14 MX MX2010011307A patent/MX2010011307A/es not_active Application Discontinuation
- 2009-04-14 US US12/423,720 patent/US20090257979A1/en not_active Abandoned
- 2009-04-14 CN CN2009801168384A patent/CN102026990A/zh active Pending
- 2009-04-14 CA CA2720846A patent/CA2720846A1/en not_active Abandoned
- 2009-04-14 BR BRPI0911259A patent/BRPI0911259A2/pt not_active IP Right Cessation
- 2009-04-14 JP JP2011505149A patent/JP2011516610A/ja active Pending
- 2009-04-14 WO PCT/US2009/040567 patent/WO2009134616A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009134616A2 (en) | 2009-11-05 |
| AU2009241514A1 (en) | 2009-11-05 |
| JP2011516610A (ja) | 2011-05-26 |
| WO2009134616A3 (en) | 2010-03-18 |
| KR20110004439A (ko) | 2011-01-13 |
| MX2010011307A (es) | 2010-11-09 |
| CA2720846A1 (en) | 2009-11-05 |
| CN102026990A (zh) | 2011-04-20 |
| US20090257979A1 (en) | 2009-10-15 |
| WO2009134616A8 (en) | 2010-05-14 |
| EP2283002A2 (en) | 2011-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0911259A2 (pt) | composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos | |
| BRPI0911260A2 (pt) | composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos | |
| BRPI0908021A2 (pt) | Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica | |
| BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BR112012002331A2 (pt) | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| EP2399910A4 (en) | NEW TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| IL209258A (en) | Derivatives of Pyrolopyridine, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0913726A2 (pt) | rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos | |
| EP2429987A4 (en) | AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| BRPI0915680A2 (pt) | miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos | |
| BR112012003148A2 (pt) | composição de remoção de oxigênio, artigo,e, uso da composição de remoção de oxigênio | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| EP2286814A4 (en) | TRANSDERMALE PREPARATION WITH PALONOSETRON | |
| BRPI0908859A2 (pt) | composição farmacêutica estabilizada de líquído único contedo docetaxel | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| BRPI0907228A2 (pt) | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos | |
| DK2391351T3 (da) | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater | |
| AP2920A (en) | Anti-malarial pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |